CRISPR/CAS 9 Technology Market Share Growing Rapidly with Recent Trends and Outlook 2021 – 2028
The ability of CRISPR/CAS 9 to correct genetic defects, yield better crop varieties, and treat human diseases has resulted in consistent market revenue growth.
According to Emergen Research, the global CRISPR/CAS 9 technology market is expected to reach USD 6,221 million by 2028, with a revenue CAGR of 20.4%. Strong global CRISPR/CAS 9 technology market revenue growth is being driven in large part by increased government and private funding. Because of CRISPR/CAS 9, a gene-editing tool, genetic engineering is undergoing significant transformation. CRISPR/CAS 9 enables scientists to precisely and rapidly alter the DNA of various species.
CRISPR/CAS 9 is a genome editing tool that allows for highly specific and rapid changes to DNA in a genome. CRISPR/CAS 9 technology has seen rapid adoption because it is more efficient, precise, and scalable than other genome editing techniques and has the ability to edit multiple loci at the same time. Rising prevalence of genetic disorders and cancers, technological advancements in gene editing, rapid adoption of CRISPR/CAS9 technology in drug discovery, and an increasing need for advanced cancer therapies are expected to drive global market revenue growth during the forecast period.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/768
COVID-19 has accelerated the growth of the mutation detection kit market. Because of the pandemic, the scientific community and market competitors are concentrating their efforts on determining the potential of gene editing techniques to prevent COVID-19 infection. CRISPR technology has been investigated as a potential tool for mitigating the effects of the pandemic and virus mutation. CRISPR can be used in a variety of ways to help improve human health.
From 2021 to 2028, the TALENs/MegaTALs technology segment is expected to grow gradually. The discovery of TALENs has resulted in significant advances in the development of new therapies. This method has been discovered to have more advanced potential gene therapy applications. The scientific community, as well as market participants in the gene therapy market, are still interested in using meganucleases in therapy development. To maintain their market presence, key market players are pursuing various strategic initiatives such as mergers and acquisitions and new product development.
Key Companies Profiled in the Report are:
Boston Merck KGaA, AstraZeneca PLC, GenScript, eGenesis, Caribou Biosciences, Inc., Horizon Discovery Group plc, Lonza, Thermo Fisher Scientific, Inc., Hera BioLabs, and Takara Bio Inc.
CRISPR/CAS 9 Technology Market Segmentation
Emergen Research has segmented the global CRISPR/CAS 9 Technology market on the basis of product & service, application, end-use, and region:
Product & Service Outlook (Revenue, USD Million; 2018–2028)
Kits & Enzymes
Cell Line Engineering
Microbial Gene Editing
Application Outlook (Revenue, USD Million; 2018–2028)
Disease Model Studies
End-use Outlook (Revenue, USD Million; 2018–2028)
Biotechnology & Pharmaceutical Companies
Contract Research Organizations (CROs)
Academics & Government Research Institutes
Request customization of the report @ https://www.emergenresearch.com/request-for-customization/768
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Visit for More Insights: https://www.emergenresearch.com/insights